Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Leuk Lymphoma. 2020 Jul;61(7):1732-1735. doi: 10.1080/10428194.2020.1728755. Epub 2020 Feb 22.
Brentuximab Vedotin (BV) is a chimeric anti-CD30 antibody, conjugated to anti-tubulin mono-methyl-auristatin. The AETHERA trial revealed increased PFS when BV is used as maintenance therapy for 16 cycles in high risk Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT). However, this schedule is associated with high cost and significant toxicity. Our objective is to assess the safety and efficacy of four cycles Brentuximab Vedotin as consolidation after ASCT for relapsed/refractory (R/R) HL. We identified 20 consecutive adult patients with R/R HL treated with BV for four cycles as consolidation after ASCT. The indications for BV consolidation included primary refractory disease in 12 patients (60%), early relapse in 6 patients (30%) and extra-nodal involvement in two patients (10%). After a median follow up of 27 months, five (25%) patients relapsed. The median time to relapse was 6 months. Median PFS and OS were not reached. No significant toxicities were reported.
本妥昔单抗维迪昔（BV）是一种嵌合抗 CD30 抗体，与抗微管单甲基澳瑞他汀结合。AETHERA 试验表明，在自体干细胞移植（ASCT）后，对于高危霍奇金淋巴瘤（HL），使用 BV 进行 16 个周期的维持治疗时，无进展生存期（PFS）增加。然而，这种方案与高成本和显著毒性相关。我们的目的是评估在 ASCT 后使用四周期本妥昔单抗维迪昔作为巩固治疗对于复发/难治性（R/R）HL 的安全性和有效性。我们鉴定了 20 例连续的 R/R HL 成年患者，他们在 ASCT 后接受了 4 个周期的 BV 巩固治疗。BV 巩固治疗的适应证包括 12 例患者（60%）的原发性难治性疾病、6 例患者（30%）的早期复发和 2 例患者（10%）的结外累及。在中位随访 27 个月后，有 5 例（25%）患者复发。复发的中位时间为 6 个月。中位无进展生存期（PFS）和总生存期（OS）尚未达到。未报告显著毒性。
